# Koloboke: Sickness Simulator

> ResidualPlay case file: an overlooked Steam game still earning residual revenue. Estimates carry a ±30-50% error range per title.

- Steam appid: 3813910
- Developer: Megame LLC
- Released: 2026 · Genre: Action · List price: $4.99
- Deal grade: D (A = dormant with >=$5k/mo opportunity, D = low signal)
- Est. net residual revenue: $591 to $887 per month (mid $739)
- Opportunity score: $739/month at x1.00 dormancy multiplier
- Est. lifetime owners: 1.7k · Est. lifetime net revenue: $2.8k
- Review sentiment: 92% positive across 76 reviews (52 from Steam purchases)
- Review velocity: 17.7 reviews/month (6-month average)

## Why it's flagged

- Developer active, last post 4 months ago
- Studio active elsewhere (4 titles tracked), so this one may welcome a partner
- Last build shipped 3 months ago
- Last discounted 0 months ago, 3 sales in the last 12 months

## Where a gross dollar goes (monthly, at current velocity)

| Stage | USD/month |
|---|---|
| Gross storefront sales | $1.3k |
| After VAT / sales tax (-13% blended) | $1.2k |
| After refunds (-9.5% median) | $1.1k |
| Net to developer (after Steam 30%) | $739 |

## Monthly review counts, oldest to newest (3 months)

44, 8, 1

## Markets by review language

- german: 2%
- english: 12%
- russian: 85%
- schinese: 2%

## Methodology

Units are estimated from Steam-purchase reviews times a release-cohort multiplier (Boxleiter method, 20-75x by year). Revenue uses an effective price (lifetime discounts and regional pricing) and nets out VAT (~13%), refunds (~9.5%) and Steam's 30% cut: roughly 55% of gross reaches the developer.

Source: https://residualplay.com/game/3813910
Citation: please cite ResidualPlay (https://residualplay.com) when using these estimates.